Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- PMID: 19680293
- PMCID: PMC2849651
- DOI: 10.1038/onc.2009.198
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Abstract
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.
Figures

Similar articles
-
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Clin Lung Cancer. 2009. PMID: 19632948 Free PMC article. Review.
-
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35810049
-
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4. Ann Oncol. 2013. PMID: 23559152
-
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1. Clin Transl Oncol. 2011. PMID: 22082647
-
Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.Curr Drug Targets. 2010 Jul;11(7):851-64. doi: 10.2174/138945010791320773. Curr Drug Targets. 2010. PMID: 20388064 Review.
Cited by
-
Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case-control study.Genes Environ. 2023 Nov 27;45(1):32. doi: 10.1186/s41021-023-00289-y. Genes Environ. 2023. PMID: 38008767 Free PMC article.
-
Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC).Sultan Qaboos Univ Med J. 2013 May;13(2):202-17. doi: 10.12816/0003225. Epub 2013 May 9. Sultan Qaboos Univ Med J. 2013. PMID: 23862025 Free PMC article.
-
Clinical application of high throughput molecular screening techniques for pharmacogenomics.Pharmgenomics Pers Med. 2011;4:109-21. doi: 10.2147/PGPM.S15302. Epub 2011 Sep 8. Pharmgenomics Pers Med. 2011. PMID: 23226057 Free PMC article.
-
k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis.Contemp Oncol (Pozn). 2016;20(2):124-9. doi: 10.5114/wo.2016.60068. Epub 2016 Jun 14. Contemp Oncol (Pozn). 2016. PMID: 27358590 Free PMC article.
-
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis.J Pers Med. 2024 Jul 15;14(7):752. doi: 10.3390/jpm14070752. J Pers Med. 2024. PMID: 39064005 Free PMC article. Review.
References
-
- Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–6501. - PubMed
-
- Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005;12(Suppl 1):S17–S27. - PubMed
-
- Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007;13(15 Suppl):4606s–4612s. - PubMed
-
- Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst. 2005;97:643–655. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous